Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424411 | 0.86 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1RAB9ANPC1 | |
| SCHEMBL29568623 | 0.86 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1RAB9ANPC1 | |
| SCHEMBL3500869 | 0.84 | NPC1 (0.66) | MAPK1HCAR3KDM4ERAB9ANPC1 | |
| SCHEMBL3500140 | 0.84 | HCAR3 (0.69) | DEGS1HCAR3RAB9ANPC1MEN1 | |
| SCHEMBL3502440 | 0.84 | NPC1 (0.66) | MAPK1HCAR3KDM4ERAB9ANPC1 | |
| SCHEMBL14505713 | 0.82 | HCAR3 (0.72) | DEGS1MAPK1HCAR3KDM4EL3MBTL1 | |
| SCHEMBL24891883 | 0.81 | DEGS1 (0.48) | DEGS1MAPK1HCAR3KDM4ERAB9A | |
| SCHEMBL30182773 | 0.81 | RAB9A (0.62) | DEGS1MAPK1HCAR3KDM4ERAB9A | |
| SCHEMBL24891679 | 0.81 | RAB9A (0.62) | DEGS1MAPK1HCAR3KDM4ERAB9A | |
| SCHEMBL3501490 | 0.81 | CXCR2 (0.57) | HCAR3KDM4ERAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2108644-B1 | N-(Methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2016-07-20 | — | — | EP | disclosed |
| EP-2108644-B1 | N-(Methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8673940-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2108644-A1 | N-(methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108644-A1 | N-(methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2102165-A2 | N-(METHYL)-1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC Immune S.A. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008061795-A2 | N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061795-A2 | N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | PSEN2, APP, PSEN1 | DEGS1 4413/4885MAPK1 530/4885HCAR3 2808/4885 |
| US-20120309791-A1 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, PSEN2, PSEN1 | DEGS1 3821/4885MAPK1 2487/4885HCAR3 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.